Tegaserod - A new 5-HT4 agonist

被引:34
作者
Lacy, BE [1 ]
Yu, SY [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Marvin M Schuster Ctr Digest & Motil Disorders, Johns Hopkins Bayview Med Ctr, Baltimore, MD 21224 USA
关键词
tegaserod; zelnorm; irritable bowel syndrome; serotonin; constipation;
D O I
10.1097/00004836-200201000-00006
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Tegaserod is a medication that has been shown to be of benefit in women with irritable bowel syndrome (IBS) associated with abdominal pain, bloating, and constipation. Tegaserod is a selective serotonin receptor subtype 4 partial agonist designed to interact with the network or cells and nerves throughout the gastrointestinal tract that use serotonin. Tegaserod has been shown to modulate both gastrointestinal motility and visceral sensitivity. Specifically, it increases the peristaltic reflex and decreases visceral sensitivity. Clinical studies have shown that tegaserod improves symptoms of abdominal pain, bloating, and constipation in women with IBS. This article discusses the role of serotonin in gastrointestinal tract physiology, the structure and pharmacokinetic profile of tegaserod, and clinical applications of this new drug.
引用
收藏
页码:27 / 33
页数:7
相关论文
共 47 条
[1]  
Appel S, 1997, CLIN PHARMACOL THER, V61, pPI85
[2]   First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine(4) receptor agonist [J].
Appel, S ;
Kumle, A ;
Hubert, M ;
Duvauchelle, T .
JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (03) :229-237
[3]   Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT4 receptor agonist, in a model of slow colonic transit [J].
Appel, S ;
Kumle, A ;
Meier, R .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (05) :546-555
[4]   The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects - male and female, elderly and young [J].
Appel-Dingemanse, A ;
Horowitz, A ;
Campestrini, J ;
Osborne, S ;
McLeod, J .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (07) :937-944
[5]   Similar pharmacokinetics of Tegaserod (HTF 919) in patients with constipation- and diarrhea-predominant irritable bowel syndrome. [J].
Appel-Dingemanse, S ;
Rawls, J ;
Heggland, J ;
Campestrini, J ;
Séchaud, R .
GASTROENTEROLOGY, 2000, 118 (04) :A1160-A1160
[6]   Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration [J].
Appel-Dingemanse, S ;
Lemarechal, MO ;
Kumle, A ;
Hubert, M ;
Legangneux, E .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (05) :483-491
[7]  
APPELDINGEMANSE S, 2000, J GASTROEN HEPATOL, V15, pA443
[8]  
APPELDINGEMANSE S, 1998, DIGESTION, V59, pA5331
[9]  
APPELDINGEMANSE S, 1996, N-S ARCH PHARMACOL, V143, P542
[10]  
BORNE RF, 1994, DRUG TOPICS, P108